Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo

2020 ◽  
Vol 28 (9) ◽  
pp. 961-969 ◽  
Author(s):  
Mingting Wang ◽  
Qin Zeng ◽  
Yuan Li ◽  
Saber Imani ◽  
Danna Xie ◽  
...  
Nanomaterials ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. 1572 ◽  
Author(s):  
Daniel Salas-Treviño ◽  
Odila Saucedo-Cárdenas ◽  
María de Jesús Loera-Arias ◽  
Humberto Rodríguez-Rocha ◽  
Aracely García-García ◽  
...  

Carbon nanotubes (CNTs) have emerged in recent years as a potential option for drug delivery, due to their high functionalization capacity. Biocompatibility and selectivity using tissue-specific biomolecules can optimize the specificity, pharmacokinetics and stability of the drug. In this study, we design, develop and characterize a drug nanovector (oxCNTs-HA-CPT) conjugating oxidated multi-wall carbon nanotubes (oxCNTs) with hyaluronate (HA) and carboplatin (CPT) as a treatment in a lung cancer model in vitro. Subsequently, we exposed TC–1 and NIH/3T3 cell lines to the nanovectors and measured cell uptake, cell viability, and oxidative stress induction. The characterization of oxCNTs-HA-CPT reveals that on their surface, they have HA. On the other hand, oxCNTs-HA-CPT were endocytosed in greater proportion by tumor cells than by fibroblasts, and likewise, the cytotoxic effect was significantly higher in tumor cells. These results show the therapeutic potential that nanovectors possess; however, future studies should be carried out to determine the death pathways involved, as well as their effect on in vivo models.


Author(s):  
Nisat Alam ◽  
Hasina Najnin ◽  
Maidul Islam ◽  
Saleem Iqbal ◽  
Rana Zaidi

Background: Cancer is caused by three factors: Nutrition, inflammation and cigarette smoke. This study in rat experimental models would enable us to understand the mechanism of lung cancer caused by NNK to which humans are continuously exposed, help us understand possible molecular targets, design drugs for humans against lung cancer. Aim: A lung cancer model was developed by administering tobacco specific carcinogen: NNK [4-methylnitrosamino)-1-(3-pyridyl)-1-butanone] to male wistar rats in 24 weeks. Further, In silico approach was followed to screen the molecular targets. Methods: A method was established in which subcutaneous and intraperitoneal injections of NNK were administered to male wistar rats simultaneously. For authentication of lung cancer in vivo we performed molecular docking simulations with protein biomarkers:Cox-2, p53, p38 MAPKs and EGFR using Hex-Discovery Studio, Schrödinger-maestro software. Results: Lung morphology and histopathology indicated the initiation of bronchiolar epithelial hyperplasia, squamous dysplasia beginning in cancer 1 group after 16 weeks NNK exposure. 66.66% incidence of squamous cell carcinoma (SCC), 33.3% incidence of adenocarcinoma in cancer 2 group after being exposed to NNK. Results indicated that the SCC and adenocarcinoma gradually increased from 66.66% to 85.71% in cancer 2 group and 33.33% to 42.58% in cancer 3 groups respectively. Docking results indicate the total binding energy and glide energy of Cox-2, p53, p38 MAPKs, EGFR : 38.14, -211.58, -181.58, - 213.05 Kcal/mol and -39.25, -32.16,-36.49, -40.19 Kcal/mol, respectively. Conclusion: Pulmonary adenocarcinoma developed in 24 weeks, in silico experiments confirm EGFR to be the most potential target for NNK induced lung Cancer.


2013 ◽  
Vol 54 (2) ◽  
pp. 148-155 ◽  
Author(s):  
Ming Jian ◽  
Zhang Qingfu ◽  
Jiang Yanduo ◽  
Jiang Guocheng ◽  
Qiu Xueshan

2012 ◽  
Vol 1 (1) ◽  
pp. 35-40 ◽  
Author(s):  
JI-YE KEE ◽  
YOSHIHISA ARITA ◽  
KANNA SHINOHARA ◽  
YASUKATA OHASHI ◽  
HIROAKI SAKURAI ◽  
...  

Cryobiology ◽  
2005 ◽  
Vol 51 (1) ◽  
pp. 92-101 ◽  
Author(s):  
Valérie Forest ◽  
Michel Peoc’h ◽  
Claude Ardiet ◽  
Lydia Campos ◽  
Denis Guyotat ◽  
...  

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Lyndsey A. Reich ◽  
Jessica A. Moerland ◽  
Ana S. Leal ◽  
Di Zhang ◽  
Sarah Carapellucci ◽  
...  

AbstractRexinoids are ligands which activate retinoid X receptors (RXRs), regulating transcription of genes involved in cancer-relevant processes. Rexinoids have anti-neoplastic activity in multiple preclinical studies. Bexarotene, used to treat cutaneous T cell lymphoma, is the only FDA-approved rexinoid. Bexarotene has also been evaluated in clinical trials for lung and metastatic breast cancer, wherein subsets of patients responded despite advanced disease. By modifying structures of known rexinoids, we can improve potency and toxicity. We previously screened a series of novel rexinoids and selected V-125 as the lead based on performance in optimized in vitro assays. To validate our screening paradigm, we tested V-125 in clinically relevant mouse models of breast and lung cancer. V-125 significantly (p < 0.001) increased time to tumor development in the MMTV-Neu breast cancer model. Treatment of established mammary tumors with V-125 significantly (p < 0.05) increased overall survival. In the A/J lung cancer model, V-125 significantly (p < 0.01) decreased number, size, and burden of lung tumors. Although bexarotene elevated triglycerides and cholesterol in these models, V-125 demonstrated an improved safety profile. These studies provide evidence that our screening paradigm predicts novel rexinoid efficacy and suggest that V-125 could be developed into a new cancer therapeutic.


2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Vasyl Kilin ◽  
Christophe Mas ◽  
Samuel Constant ◽  
Jean-Pierre Wolf ◽  
Luigi Bonacina

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Vasyl Kilin ◽  
Christophe Mas ◽  
Samuel Constant ◽  
Jean-Pierre Wolf ◽  
Luigi Bonacina

Sign in / Sign up

Export Citation Format

Share Document